Once again I will await the trial report to see whether or not it was significant. It is not the size of the trial or the speed of the trial that makes it significant...but rather WHAT THEY LEARNED FROM IT. It may in fact have been very important in shaping their decision to move ahead with a phase II trial using the combination of Bavi and ribavirin. Once again I can only say that Bavi results as a cancer monotherapy were not encouraging but the combination trial results are very good. If the combination therapy HCV trial follows that same pattern we may all be pleasantly surprised. Hopefully we will get some news by the middle of this year.
Market Data 
Markets 
AI
